These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 29757530

  • 1. NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.
    Wynn P.
    Diabetes Self Manag; 2017 Mar; 34(2):24-7, 31. PubMed ID: 29757530
    [No Abstract] [Full Text] [Related]

  • 2. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I, Pettus JH, Santos Cavaiola T.
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [Abstract] [Full Text] [Related]

  • 3. The New Wave.
    Neithercott T.
    Diabetes Forecast; 2016 May; 69(2):42-5. PubMed ID: 27048047
    [No Abstract] [Full Text] [Related]

  • 4. More Consumer Diabetes Products Using Technology to Get--and Stay--Connected.
    Dubois W.
    Diabetes Self Manag; 2016 May; 33(2):36-8, 40, 42. PubMed ID: 27086399
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L, Knop FK, Vilsbøll T.
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tools of the trade 2013.
    Cooper A.
    Diabetes Self Manag; 2013 May; 30(6):34, 36, 39-40. PubMed ID: 24417005
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
    Gómez AM, Marín Sánchez A, Muñoz OM, Colón Peña CA.
    Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
    [Abstract] [Full Text] [Related]

  • 13. Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
    Paul SK, Agbeve J, Maggs D, Best JH.
    J Diabetes; 2016 Jan; 8(1):148-57. PubMed ID: 25586464
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T, Mine Y, Aoki M, Okuno M, Suzuki J.
    Endocr J; 2017 Feb 27; 64(2):133-140. PubMed ID: 27746408
    [Abstract] [Full Text] [Related]

  • 16. Treatment of transient neonatal diabetes mellitus: insulin pump or insulin glargine? Our experience.
    Passanisi S, Timpanaro T, Lo Presti D, Mammì C, Caruso-Nicoletti M.
    Diabetes Technol Ther; 2014 Dec 27; 16(12):880-4. PubMed ID: 25437016
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin.
    Johnson EL, Frias JP, Trujillo JM.
    Postgrad Med; 2018 May 27; 130(4):365-374. PubMed ID: 29569978
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.